Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies

Patients with hematologic malignancies are reported to have a more severe course of coronavirus disease 2019 (COVID-19) and be less responsive to vaccination. In this prospective study, we aimed to evaluate the serological responses to booster COVID-19 vaccines of Taiwanese patients with hematologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chien-Tzu, Lee, Ching-Ping, Chen, Tzu-Yin, Liu, Yi-Chang, Cho, Shih-Feng, Du, Jeng-Shiun, Yu, Ming-Lung, Huang, Chung-Feng, Wang, Sheng-Fan, Hsiao, Hui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488979/
https://www.ncbi.nlm.nih.gov/pubmed/37685720
http://dx.doi.org/10.3390/jcm12175647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488979/
https://www.ncbi.nlm.nih.gov/pubmed/37685720
http://dx.doi.org/10.3390/jcm12175647

Ejemplares similares